Table 1.
Market status of BZD/Z hypnotics and PR-melatonin for each country in the scope
| Anti-BZD campaigns | PR-melatonin | BZD/Z-drugs | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Countries | Yes/No | year | Launch date | Promotion | Reimbursement | Volume market share in 2011 (SU%) | Price (€/tab) | Reimbursement | Volume market size in 2005 (million SU) | Zolpidem price (€/tab) |
| Finland | Yes | 2005 | January 2008 | Actively promoted | No reimbursement | 5.10 % | 0.55 | Partial reimbursement | 105,962 | 0.07 |
| Norway | Yes | 2005 | January 2008 | Actively promoted | No reimbursement | 4.50 % | 0.53 | No reimbursement | 75,711 | 0.10 |
| Denmark | Yes | 2008 | October 2007 | Actively promoted | No reimbursement | 3.70 % | 0.55 | No reimbursement | 71,688 | 0.63 |
| Sweden | Yes | 2001 | 2008 | Actively promoted | No reimbursement | 1 % | 0.62 | Reimbursed | 195,048 | 0.05 |
| Greece | No | – | 2008 | Actively promoted | Reimbursed (automatic, at 75 %) | 5.50 % | 0.53 | Reimbursed (automatic, at 75 %) | 50,836 | 0.09 |
| France | Yes | 2008 | June 2008 | Not promoted | No reimbursement | <1 % | 0.76 | Reimbursed | 766,207 | 0.16 |
| Netherlands | Yes | 2009 | 2009 | Initially promoted | No reimbursement | <1 % | 0.57 | No reimbursement (since Jan 2009) | 148,042 | Not found |
| UK | Yes | 2004 | 2008 | Initially promoted | Reimbursed (automatic) not recommended by NICEa | <1 % | 0.53 | Reimbursed (automatic) | 474,775 | 0.08 |
| Equal recommendation BZD and Z drugs by NICE | ||||||||||
| Spain | Regional small campaigns | – | Not launched | NA | NA | NA | NA | Reimbursed | 390,005 | 0.06 |
aIn the UK, drug prices are freely chosen by pharmaceutical firms and reimbursed at 100 %. The control of practices is made through the recommendations of the National Health Service (NHS) after advice from the National Institute for Health and Clinical Excellence (NICE). In a general way, a product negatively recommended is not prescribed.